 Clinical Trials, Phase III as Topic
"Clinical Trials, Phase III as Topic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
| Descriptor ID |
D017326
|
| MeSH Number(s) |
E05.318.760.535.220 E05.337.250.220 N05.715.360.775.235.220 N06.850.520.450.535.220
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clinical Trials, Phase III as Topic".
Below are MeSH descriptors whose meaning is more specific than "Clinical Trials, Phase III as Topic".
This graph shows the total number of publications written about "Clinical Trials, Phase III as Topic" by people in this website by year, and whether "Clinical Trials, Phase III as Topic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 0 | 4 | 4 | | 1995 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 3 | 3 | | 2003 | 0 | 2 | 2 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 8 | 8 | | 2006 | 2 | 4 | 6 | | 2007 | 0 | 3 | 3 | | 2008 | 2 | 1 | 3 | | 2009 | 0 | 5 | 5 | | 2010 | 0 | 9 | 9 | | 2011 | 0 | 15 | 15 | | 2012 | 3 | 2 | 5 | | 2013 | 1 | 7 | 8 | | 2014 | 1 | 8 | 9 | | 2015 | 0 | 4 | 4 | | 2016 | 1 | 7 | 8 | | 2017 | 0 | 7 | 7 | | 2018 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Clinical Trials, Phase III as Topic" by people in Profiles.
-
Fam MD, Stadnik A, Zeineddine HA, Girard R, Mayo S, Dlugash R, McBee N, Lane K, Mould WA, Ziai W, Hanley D, Awad IA. Symptomatic Hemorrhagic Complications in Clot Lysis: Evaluation of Accelerated Resolution of Intraventricular Hemorrhage Phase III Clinical Trial (CLEAR III): A Posthoc Root-Cause Analysis. Neurosurgery. 2018 12 01; 83(6):1260-1268.
-
Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 09; 100:35-45.
-
Patel JD, Chmura SJ. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer? Cancer. 2018 07 15; 124(14):2878-2880.
-
Patel JD, Paz-Ares L, Zinner RG, Barlesi F, Koustenis AG, Obasaju CK. Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care. Clin Lung Cancer. 2018 11; 19(6):e823-e830.
-
Haddad RI, Posner M, Hitt R, Cohen EEW, Schulten J, Lefebvre JL, Vermorken JB. Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions. Ann Oncol. 2018 05 01; 29(5):1130-1140.
-
McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018 04 15; 121(8):940-948.
-
Erbe AK, Wang W, Carmichael L, Kim K, Mendonça EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman AL, Yu AL, Sondel PM. Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clin Cancer Res. 2018 01 01; 24(1):189-196.
-
Misiukiewicz K, Gupta V, Posner M. The Italian Collaborative Group sets a standard for the treatment of locally advanced head and neck cancer. Ann Oncol. 2017 09 01; 28(9):2051-2054.
-
Viswanathan HN, Mutebi A, Milmont CE, Gordon K, Wilson H, Zhang H, Klekotka PA, Revicki DA, Augustin M, Kricorian G, Nirula A, Strober B. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health. 2017 09; 20(8):1174-1179.
-
Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|